The effect of lasofoxifene on local mediators of bone resorption in the prevention of postmenopausal osteoporosis.
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2011
At a glance
- Drugs Lasofoxifene (Primary)
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms LACE
- Sponsors Pfizer
- 19 Jul 2011 Additional drug company added in associations field as reported by ClinicalTrials.gov record.
- 01 Dec 2009 Results reported in Bone.
- 12 Sep 2008 Results reported at ASBMS.